Artiva Biotherapeutics, Inc. (ARTV) Posts Phase 2a AlloNK Gains in Sjögren Disease

Artiva reported updated Phase 2a AlloNK plus rituximab data in 11 Sjögren patients with ≥6 months follow-up, showing mean ClinESSDAI −6.9 and ESSPRI −3.5 at 6 months, with no CRS or ICANS observed across 73 patients in the basket study.Material DetailsContext by AI AnalystThis is mid-stage clinical…